CTI Announces Data Presentations at the 55th ASH Annual Meeting

Cell Therapeutics, Inc. (CTI) has announced the upcoming presentations of data highlighting pacritinib, a novel, oral JAK2/FLT3 inhibitor, and tosedostat, an aminopeptidase inhibitor, at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2013 in New Orleans, LA.

The presentations will include data from additional analyses of completed Phase 2 trials of pacritinib in patients with myelofibrosis and data from investigator-sponsored clinical trials of tosedostat for first line acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and a separate study in relapsed patients.

A summary of the presentations is below, and full abstracts can be accessed on the ASH website at www.hematology.org.

Oral Presentation

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis of Phase II Trial Data in Patients with Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤ 100,000 µL

• First Author: Dr. Srdan Verstovsek, MD Anderson Cancer Center, Houston, TX
• Date/Time: Monday, December 9, 2013 at 11:30 a.m. CT
• Location: Theater C
• Oral Session: 634, Myeloproliferative Syndromes: Clinical I
• Abstract #395

Poster Presentations

A Phase I/II Study of Cytarabine or Azacitidine in Combination with Tosedostat in Older Patients with AML or High-Risk MDS

• First Author: Dr. Courtney DiNardo, MD Anderson Cancer Center, Houston, TX
• Date/Time: Sunday, December 8, 2013, 6:30-8:30 p.m. CT
• Location: Hall E
• Poster Presentation: 615, Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster II
• Abstract #2698

A Phase II Study of Tosedostat (TST) in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

• First Author: Dr. Raya Mawad, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
• Date/Time: Monday, December 9, 2013, 6:00-8:00 p.m. CT
• Location: Hall E
• Poster Presentation: 615, Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster III
• Abstract #3926

Exposure-Response Analysis for Pacritinib (SB1518), a Novel Oral JAK2/FLT3 Inhibitor, In Patients With Myelofibrosis

• First Author: Dr. Suliman Al-Fayoumi, Cell Therapeutics, Inc., Seattle, WA
• Date/Time: Monday, December 9, 2013 at 6:00-8:00 p.m. CT
• Location: Hall E
• Poster Presentation: 634, Myeloproliferative Syndromes: Clinical: Poster III
• Abstract #4080